Anti-VEGF inhibitors and their role in the treatment of diabetic macular oedema;Die rolle der Anti-VEGF-therapie in der behandlung desdiabetischen makuladems

Klinische Monatsblatter fur Augenheilkunde

Volumn 227, Issue 9, 2010, Pages 701-711

  Kakkassery, V ^a   Winterhalter, S ^a   Joussen, A M ^a  

^a Charitéitäzin Berlin   (Germany)

Author keywords

anti VEGF therapy; diabetic macular oedema; retina

Indexed keywords

VASCULOTROPIN ANTIBODY;

BLINDNESS; CAUSAL ATTRIBUTION; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG SAFETY; GOLD STANDARD; HUMAN; IMMUNOTHERAPY; LASER COAGULATION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; BLOOD-RETINAL BARRIER; CAPILLARY PERMEABILITY; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; MIDDLE AGED; OFF-LABEL USE; RECOMBINANT FUSION PROTEINS; RETINOSCOPY; TRIAMCINOLONE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77956892614     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1245718     Document Type: Review

References (60)

1. Wild S, Roglic G, Green A et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004 27 1047-1053
2. Moss S E., Klein R, Klein B E. Ten-year incidence of visual loss in a diabetic population. Ophthalmology 1994 101 1061-1070
3. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology 1978 85 82-106
4. Beetham W P., Aiello L M., Balodimos M C. et al. Ruby laser photocoagulation of early diabetic neovascular retinopathy. Preliminary report of a long-term controlled study. Arch Ophthalmol 1970 83 261-272
5. Lang G E. New developments in the treatment of diabetic macular oedema. Klin Monbl Augenheilkd 2003 220 519
6. Bresnick G H. Diabetic macular edema. A review. Ophthalmology 1986 93 989-997
7. Kinyoun J, Barton F, Fisher M et al. Detection of diabetic macular edema. Ophthalmoscopy versus photography Early Treatment Diabetic Retinopathy Study Report Number 5. The ETDRS Research Group. Ophthalmology 1989 96 746-750 discussion 750 741
8. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1987 94 761-774
9. Wilkinson C P., Ferris 3rd F L., Klein R E. et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003 110 1677-1682
10. Patz A, Finkelstein D, Fine S L. et al. The role of fluorescein angiography in national collaborative studies. Ophthalmology 1986 93 1466-1470
11. Browning D J., Altaweel M M., Bressler N M. et al. Diabetic macular edema: what is focal and what is diffuse? Am J Ophthalmol 2008 146 649-655
12. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008 115 1447-1449
13. Beck R W., Edwards A R., Aiello L P. et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009 127 245-251
14. Gragoudas E S., Adamis A P., Cunningham E T. et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004 351 2805-2816
15. DAmico D J., Masonson H N., Patel M Jr et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006 113 992-1001, e1006
16. Heier J S., Antoszyk A N., Pavan P R. et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006 113 633, e631-e634
17. Rosenfeld P J., Schwartz S D., Blumenkranz M S. et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005 112 1048-1053
18. Presta L G., Chen H, OConnor S J. et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997 57 4593-4599
19. Scott I U., Edwards A R., Beck R W. et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007 114 1860-1867
20. Nguyen Q D., Shah S M., Heier J S. et al. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2009 116 2175-2181, e2171
21. Cunningham E T., Adamis A P., Altaweel M Jr et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005 112 1747-1757
22. Do D V., Nguyen Q D., Shah S M. et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. Br J Ophthalmol 2009 93 144-149
23. Duke-Elder S, Dobree J H. The formation of avascular connective-tissue bands in proliferative diabetic retinopathy. Bibl Ophthalmol 1968 76 133-138
24. Behzadian M A., Windsor L J., Ghaly N et al. VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. Faseb J 2003 17 752-754
25. Deissler H, Deissler H, Lang G K. et al. Generation and characterization of iBREC: novel hTERT-immortalized bovine retinal endothelial cells. Int J Mol Med 2005 16 65-70
26. Deissler H, Deissler H, Lang S et al. VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells. Br J Ophthalmol 2008 92 839-843
27. Tolentino M J., Miller J W., Gragoudas E S. et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996 103 1820-1828
28. Tolentino M J., McLeod D S., Taomoto M et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 2002 133 373-385
29. Qaum T, Xu Q, Joussen A M. et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001 42 2408-2413 (Pubitemid 32848873)
30. Aiello L P., Avery R L., Arrigg P G. et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994 331 1480-1487
31. Boulton M, Foreman D, Williams G et al. VEGF localisation in diabetic retinopathy. Br J Ophthalmol 1998 82 561-568
32. Smith G, McLeod D, Foreman D et al. Immunolocalisation of the VEGF receptors FLT-1, KDR, and FLT-4 in diabetic retinopathy. Br J Ophthalmol 1999 83 486-494
33. Campochiaro P A., Choy D F., Do D V. et al. Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology 2009 116 2158-2164
34. Kumar A, Sinha S. Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Indian J Ophthalmol 2007 55 451-455
35. Ahmadieh H, Ramezani A, Shoeibi N et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema, a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2008 246 483-489 (Pubitemid 351447960)
36. Faghihi H, Roohipoor R, Mohammadi S F. et al. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol 2008 18 941-948
37. Kook D, Wolf A, Kreutzer T et al. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina 2008 28 1053-1060
38. Paccola L, Costa R A., Folgosa M S. et al. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 2008 92 76-80
39. Fang X, Sakaguchi H, Gomi F et al. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema. Acta Ophthalmol 2008 86 800-805
40. Shimura M, Nakazawa T, Yasuda K et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008 145 854-861
41. Bonini-Filho M, Costa R A., Calucci D et al. Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study. Am J Ophthalmol 2009 147 1022-1030
42. Lam D S., Lai T Y., Lee V Y. et al. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial. Retina 2009 29 292-299
43. Seo J W., Park I W. Intravitreal bevacizumab for treatment of diabetic macular edema. Korean J Ophthalmol 2009 23 17-22
44. Soheilian M, Ramezani A, Obudi A et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009 116 1142-1150
45. Soheilian M, Ramezani A, Bijanzadeh B et al. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 2007 27 1187-1195
46. Velez-Montoya R, Fromow-Guerra J, Burgos O et al. The effect of unilateral intravitreal bevacizumab (avastin), in the treatment of diffuse bilateral diabetic macular edema: a pilot study. Retina 2009 29 20-26
47. Forte R, Cennamo G L., Finelli M et al. Intravitreal bevacizumab vs intravitreal triamcinolone combined with macular laser grid for diffuse diabetic macular oedema. Eye 2010 24 (8) 1325-1330
48. Kreutzer T C., Al Saeidi R, Kook D et al. Comparison of Intravitreal Bevacizumab versus Triamcinolone for the Treatment of Diffuse Diabetic Macular Edema. Ophthalmologica 2010 224 258-264
49. Haritoglou C, Kook D, Neubauer A et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006 26 999-1005
50. Arevalo J F., Sanchez J G., Fromow-Guerra J et al. Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. Graefes Arch Clin Exp Ophthalmol 2009 247 735-743
51. Arevalo J F., Sanchez J G., Wu L et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology 2009 116 1488-1497
52. Michaelides M, Kaines A, Hamilton R D. et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010 117 1078-1086
53. Michaelides M, Fraser-Bell S, Hamilton R et al. Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study). Retina 2010 30 781-786
54. Adamis A P., Altaweel M, Bressler N M. et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006 113 23-28
55. Querques G, Bux A V., Martinelli D et al. Intravitreal pegaptanib sodium (Macugen) for diabetic macular oedema. Acta Ophthalmol 2009 87 623-630
56. Chun D W., Heier J S., Topping T M. et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006 113 1706-1712
57. Nguyen Q D., Tatlipinar S, Shah S M. et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006 142 961-969
58. Elman M J., Aiello L P., Beck R W. et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010 117 1064-1077 e1035
59. Schmucker C, Ehlken C, Hansen L L. et al. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Curr Opin Ophthalmol 2010 21 218-226
60. Querques G, Bux A V., Martinelli D et al. Short-term fluctuation of diabetic macular edema after intravitreal ranibizumab injection. Retina 2009 29 1274-1281